XDx marks a spot: An $86M IPO for gene-expression diagnostics
(UPDATED: See below.)
When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane, Calif., company joined just a handful of similar molecular-diagnostic companies to test the public markets. XDx specializes in a new type of diagnostic test that measures gene activity — technically, “gene expression” — in blood.
Gene-expression diagnostics have only been around for a few years, and they’re been slow to catch on. The tests use “gene chips” that measure the… Continue Reading